According to two new studies, Johnson & Johnson’s Zytiga helped men newly diagnosed with advanced prostate cancer live longer, according to a Bloomberg article.
Men who received hormone therapy and Zytiga were about one-third less likely to die during the studies than those who received standard treatment alone, according to research recently presented at the American Society of Clinical Oncology meeting. The the drug is currently used to treat men who worsen after getting standard hormone therapy, but findings show it should be given before the cancer starts to spread.
Read the full story